BioSpace News Archive

Drug Development

Initial Results from MOUNTAINEER Trial Show Antitumor Activity of Tucatinib Combination in HER2-Positive Metastatic Colorectal Cancer

Seattle Genetics, Inc. announced that initial data were presented from the single arm phase 2 clinical trial known as MOUNTAINEER.

September 29, 2019
·
7 min read
Pharm Country

Novartis Kisqali® delivers consistently superior overall survival - MONALEESA-3 trial demonstrates more life for postmenopausal HR+/HER2- advanced breast cancer patients

Novartis announced results from the MONALEESA-3 trial, which showed Kisqali® (ribociclib) achieved statistically significant improvement in overall survival (OS).

September 29, 2019
·
12 min read
Verzenio® (abemaciclib) Significantly Extends Life by a Median of 9.4 Months for Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2 Study

Verzenio plus fulvestrant significantly extended life to a median of 46.7 months vs. 37.3 months compared to fulvestrant alone - MONARCH 2 showed statistically significant results for women whose disease progressed following endocrine therapy

September 29, 2019
·
23 min read
Drug Development

Kinoxis Therapeutics Awarded NIH HEAL Initiative Grant to Advance KNX100 for the Treatment of Opioid Withdrawal

Kinoxis Therapeutics Pty Ltd has been awarded a major grant from the US National Institutes of Health, National Institute on Drug Abuse (NIH/NIDA).

September 29, 2019
·
4 min read
Biotech Bay

Edwards SAPIEN 3 TAVR Demonstrates Significant Health Status Improvements for Low-Risk Patients

Edwards Lifesciences Corporation announced new data demonstrating early and sustained health status advantages for severe aortic stenosis patients at low surgical risk treated with the Edwards SAPIEN 3 valve.

September 29, 2019
·
4 min read
Job Trends

Elevar Announces Results from the ANGEL trial, a study of Monotherapy Rivoceranib (Apatinib) in Late-Stage Gastric Cancer Patients

Elevar Therapeutics announced data from the ANGEL trial, a randomized phase 3 study of rivoceranib plus best supportive care in patients with gastric or gastroesophageal junction cancer who have failed at least 2 prior lines of therapy.

September 29, 2019
·
4 min read
Drug Development

ImmunoGen Presents Full Data from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer at ESMO

FORWARD I Did Not Meet Primary Endpoint of Progression-Free Survival; Promising Efficacy Results Seen in Folate Receptor Alpha (FRα) High Patients

September 29, 2019
·
11 min read
Drug Development

Clover Biopharmaceuticals Doses First Patient in Phase I Study of SCB-313 in China for Malignant Ascites

Clover Biopharmaceuticals announced that the first patient was dosed in another Phase I trial of SCB-313, an investigational fully-human TRAIL-Trimer fusion protein, in China for the treatment of cancer patients with malignant ascites.

September 29, 2019
·
4 min read
Drug Development

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Statistically Significant Increase in Pathological Complete Response Versus Chemotherapy as Neoadjuvant Therapy in Early-Stage Triple-Negative Breast Cancer (TNBC)

Interim Results from Pivotal Neoadjuvant/Adjuvant Phase 3 KEYNOTE-522 Trial Presented for the First Time at ESMO 2019 Congress During Presidential Symposium

September 29, 2019
·
34 min read
New Major Order From China

Bactiguard has received a new order from Well Lead Medical (Well Lead) in China. The order will be delivered promptly and generate revenues in the third quarter of approximately SEK 4,8 million.

September 29, 2019
·
1 min read